Subscribe to Drug Discovery & Development Articles
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Faking Fluorescence

April 9, 2014 11:05 am | by Takeharu Nagai, Ph.D., Osaka University, Japan | Comments

The world’s brightest luminescent protein, a discovery dubbed the “Nano-lantern,” is lighting up the future of in vivo imaging– without the use of external light. This could benefit more advanced applications, such as high-throughput drug screening and single-cell tracking in live animals and plants.


Druggable Link Found Between Inflammation, Breast Cancer Stem Cells

March 4, 2014 3:47 pm | by Cynthia Fox, Science Editor | Comments

In the deadliest breast cancers, a protein driving inflammation fails to shut down, prompting increases in cancer stem cells, according to new research. This new link gives researchers a new potential target for treating triple-negative breast cancer (TNBC). The research indicates that drugs that should potentially be tried on breast cancer patients in clinical trial include over-the-counter anti-inflammatories like aspirin and Naproxen.


New Therapy Targets Prospective Older Bone Marrow Transplant Patients

February 20, 2014 9:45 am | by Kaushik J. Dave, Ph.D. | Comments

Bone marrow transplants are the only potential cure for many blood cancers in older patients, but many in this group are ruled ineligible because the procedure is often deemed too harsh for older people. Since more than half of AML patients are over 65 years old, new tactics to prepare these patients for hematopoietic stem cell transplantation are needed.


Innovative Academics to Work Elbow-to-Elbow with Big Pharma

February 5, 2014 9:47 am | by Cynthia Fox, Science Editor | Comments

The new $650 million Belfer Research Building at the Weill Cornell Medical College will shake up research by offering an entire floor for academics and industry to work elbow-to-elbow in the same labs. Read more...


At-Home Alzheimer’s Test Goes Viral

January 30, 2014 10:59 am | by Cynthia Fox, Science Editor | Comments

A cheap, short, at-home Alzheimer’s disease test went so viral the academic website selling it briefly shut down, according to reports. The SAGE test is a community cognitive screening tool, aimed at catching Alzheimer’s earlier and offering a potential cognitive function baseline. Read more...


Building Blocks for the Solid-Phase Synthesis of Peptide Pharmaceuticals

January 29, 2014 11:09 am | by Marc Jacob, Product Manager, Phenomenex | Phenomenex | Comments

The advantage of solid-phase peptide synthesis (SPPS) this technique is that peptides can be built efficiently with a standard reaction procedure that is well-suited for automation. So what happens during the chiral separation of FMOC-protected amino acids for SPPS, using polysaccharide-based CSPs under reversed-phase (RP) mode? Find out...


Using Smart Instruments and Infrastructure to Improve Data Reliability

January 21, 2014 10:11 am | by Nicole Keppy, Senior Product Specialist, UV-Visible Spectroscopy, Thermo Fisher Scientific; and David Joyce, Senior Product Manager, Laboratory Informatics, Thermo Fisher Scientific | Thermo Fisher Scientific | Comments

Safe pharmaceuticals may be the end goal of pharmaceutical QA/QC laboratories, but reliable, accurate and accessible data is what makes that goal possible. When data isn’t collected and organized well, labs become inaccurate and inefficient, which can result in delays– and even product recalls.


Turning Ancient Chinese Meds into Modern Drugs

January 16, 2014 9:56 am | by Cynthia Fox, Science Editor | Comments

An East-West team has created a potential anti-pain drug out of a traditional Chinese herbal medicine. The drug appears to be non-addictive, and eases both inflammatory and neuropathic pain. So what's next for the newly discovered compound? Find out...


The Road More Traveled: Improving Drug Therapies for Not-So-Rare Diseases

January 15, 2014 9:27 am | by Seth Lederman, MD, CEO, Tonix Pharmaceuticals | Comments

To borrow a line from Robert Frost’s famous poem, for big and small patient populations, two roads are diverging in drug development. Traditional pharmaceutical developers tackle common problems affecting the many; orphan drug and personalized medicine developers target rare problems affecting few people. But which road is more traveled now? Find out...


Single Cell Sequencing Technique May Double IVF Success

January 14, 2014 9:32 am | by Cynthia Fox, Science Editor | Comments

A new gene sequencing approach may give in vitro fertilization (IVF) doctors a potentially less invasive, and more successful, IVF method, according to a new study. The team behind the study believes the new approach may double IVF success rates.


Stability of Biologics at High Concentrations

January 10, 2014 10:43 am | Comments

The optimization of formulation conditions for highly concentrated biologics necessitates stability evaluation at the required protein concentrations for administration (~100 mg/mL). Traditional techniques either lack the dynamic range to measure protein stability over a wide range of concentrations, or the physical perturbation by itself induces protein aggregation. Read more...


Simplifying UHPLC

January 9, 2014 11:50 am | by Mike May, Contributing Editor | Comments

In drug research, the science of separation comes into many aspects of discovery and development. Today much of that separation involves ultra high-performance liquid chromatography (UHPLC). So what are the latest trends in UHPLC technology? Find out...


Orphans No Longer

January 9, 2014 9:11 am | by Ted Agres, Contributing Editor | Comments

With worldwide markets for prescription drugs stagnating, pharmaceutical companies are eyeing small-population “orphan drugs” as big moneymakers. Despite their relatively limited populations, drugs for rare diseases have already demonstrated significant financial value. Read more...


Strategies for Development and Validation of Immunogenicity Assays to Support Preclinical and Clinical Biosimilar Programs

January 9, 2014 8:00 am | by Kelly S. Colletti, PhD, MBA, Charles River Laboratories | Comments

An area of intense focus in the preclinical and clinical testing of biosimilars is the measurement of anti-drug antibodies and the comparison of relative immunogenicity rates of the biosimilar and the reference products.  Although the draft FDA guidance for biosimilars was issued, there is a clear lack of detail in the description of how these assays should be developed, validated and implemented within a biosimilar program. Read more...


Avoiding Facilities Equipment Failure Through PMO

January 9, 2014 8:00 am | by By Dick Auger, Vice President, cGxP Center of Excellence, Life Sciences, Jones Lang LaSalle | Comments

All facilities equipment fails eventually. Electrical, heating, ventilation and cooling systems involve a multitude of equipment types, including machines with dozens of components that can malfunction at any time. Is it a disaster if one minor component fails? What if the failure of that component triggers a cascade of problems leading to a total shutdown? For a life sciences facility, the event can be devastating. Read more...



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.